Cannabis
Rescheduling

Cannabis rescheduling refers to the process of moving marijuana from Schedule I to Schedule III under the US Controlled Substances Act. Schedule I is reserved for substances the federal government considers to have no accepted medical use and a high potential for abuse — a category that has historically included heroin and LSD. Schedule III covers substances with accepted medical uses and a moderate-to-low potential for dependence.

The reclassification would not legalise cannabis federally, but it would meaningfully change how it is regulated, taxed and researched.

Movement on rescheduling has occurred — including executive action and DEA hearings — but the process has been marked by delays, witness disputes and political resistance. The current state is best described as actively contested: parts of the federal government have moved, others have not, and the rule's full effect on operators is still being worked through.

For the most up-to-date status, see The US Officially Reschedules Cannabis — Partly and The Fight Is Far From Over.

The single biggest commercial impact of moving to Schedule III is the end of IRC Section 280E, the tax provision that prevents cannabis operators from deducting ordinary business expenses. Removing 280E would materially improve cash flow for nearly every plant-touching operator, particularly multi-state operators (MSOs) carrying heavy effective tax burdens.

Beyond tax, rescheduling would expand legal research access, change the calculus around banking, and reshape investor sentiment toward the sector. See our reporting on the MSO tax exposure.

No. Rescheduling moves cannabis to a different category within the Controlled Substances Act — it does not legalise cannabis at the federal level. Recreational cannabis would remain federally controlled, and existing state markets would continue to operate within their own legal frameworks. Federal legalisation would require an act of Congress, not an administrative rescheduling.

The DEA's rulemaking process has been delayed by witness disputes, lawsuits, allegations of agency bias, leadership changes, and political pressure from Capitol Hill. Multiple participants have challenged the DEA's conduct — and the agency itself has navigated subpoena requests, hearing reschedules and a change in administrator. See our DEA & Legal Process cluster for the full chronology.

Cannabis equities have moved sharply on every major rescheduling signal — rallying on positive announcements and selling off on delays. The pattern is now well-established enough that some analysts characterise rescheduling-driven moves as their own discrete trading regime.

For ongoing market reaction, see our Cannabis Stocks Hub.

Yes — and political opposition has explicitly sought to do so. Republican lawmakers have introduced legislation to block 280E relief even if cannabis is rescheduled, and US spending bills have included provisions targeting funding for the rescheduling process. The administrative pathway is also subject to legal challenge. Anyone modelling the impact of rescheduling needs to account for the realistic possibility of partial rollback.

The 29 June 2026 administrative hearing will decide whether the existing Schedule III rule — currently scoped to medical cannabis — is extended to cover recreational (adult-use) cannabis. It is the next major procedural milestone after the initial rescheduling took effect.

Three separate legal challenges are now seeking to derail the hearing: a petition by the attorneys general of Nebraska, Indiana and Louisiana; a consolidated challenge from Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association; and a pharmaceutical-industry coalition led by MMJ International Holdings arguing the rule creates an unconstitutional "hybrid schedule." See our full report.

As of June 2026, formal Treasury and IRS implementation guidance on 280E relief remains outstanding — five weeks after the rescheduling rule was announced. Seven House Democrats wrote to the IRS on 28 May urging the agency to publish guidance, citing the three-year statutory window that limits operators' ability to amend prior returns and claim refunds for overpaid tax.

Until guidance lands, plant-touching operators face uncertainty on the timing and scope of refund claims for prior years. See our MSO tax exposure analysis.

US rescheduling has outsized influence on international markets — both because of US capital flows and because it shapes the regulatory model other countries reference. European operators, in particular, have begun to rethink US strategy in response, with Cannabis Europa London 2026 expected to be the first major industry gathering to formally take stock of the shift. See our preview.